A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)
A study for patients with Idiopathic Parkinson's Disease using study drug CVT-301
Sponsor: Acorda Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAO4151
U.S. Govt. ID: NCT02240030
Contact: Amber Servi: 212-305-3665 / ads2178@columbia.edu
Additional Study Information: The purpose of this research is to find out whether an investigational drug called CVT-301, is helpful to people with Parkinson's Disease (PD). The treatment involves a new method for taking levodopa (LD) through an inhaler (which is like an asthma inhaler) to provide relief of motor fluctuations (OFF episodes), which are experienced by many Parkinson's disease patients.
This study is closed
Cheryl Waters, MD
Do You Qualify?
Have you been diagnosed with Idiopathic Parkinson's Disease (PD)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Amber Servi